ClinicalTrialsFinder
RecruitingPhase 1NCT07081503

Phase 1 Study of ADX-626 in Healthy Participants

A Phase 1, Randomized, Blinded, Placebo-Controlled Study to Assess ADX-626 in Healthy Participants

Sponsor

ADARx Pharmaceuticals, Inc.

Enrollment

44 participants

Start Date

Aug 12, 2025

Study Type

INTERVENTIONAL

Conditions

healthy adult participants

Summary

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ADX-626 and a drug called Placebo for people with healthy adult participants. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGADX-626

siRNA duplex oligonucleotide

DRUGPlacebo

Saline

Locations(1)

Richmond Pharmacology

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07081503

Related Trials

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

NCT07798505

Phase 1 Study Involving SAB01 and Healthy Participants

NCT07815561

The Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors

NCT07815496

RIG 101 Trial in Healthy Adults and Adults With Asthma

NCT074888972 locations

Alpelisib Challenge Test (ACT)

NCT07778524